Which thiazide to choose as add-on therapy for hypertension?

Abstract: Combined therapy is required in the majority of patients with hypertension to achieve blood pressure (BP) targets. Although different antihypertensive drugs can be combined, not all combinations are equally effective and safe. In this context, the combination of a renin angiotensin system inhibitor with a diuretic, usually a thiazide, particularly hydrochlorothiazide (HCTZ) or thiazide-like diuretics, such as chlorthalidone or indapamide, is recommended. However, not all diuretics are equal. Although HCTZ, chlorthalidone, and indapamide as add-on therapy effectively reduce BP levels, the majority of studies have obtained greater BP reductions with chlorthalidone or indapamide than with HCTZ. Moreover, there are data showing benefits with chlorthalidone or indapamide beyond BP. Thus, chlorthalidone seems to have pleiotropic effects beyond BP reduction. Moreover, compared with placebo, chlorthalidone has small effects on fasting glucose and total cholesterol, and compared with HCTZ, chlorthalidone achieves significantly lower total cholesterol and low-density lipoprotein cholesterol levels. Similarly, indapamide has demonstrated no negative impact on glucose or lipid metabolism. More importantly, although head-to-head clinical trials comparing the effects of indapamide or chlorthalidone with HCTZ are not available, indirect comparisons and post hoc analyses suggest that the use of chlorthalidone or indapamide is associated with a reduction in cardiovascular events. Despite this, the most frequent diuretic used in clinical practice as add-on therapy for hypertension is HCTZ. The purpose of this review is to update the published data on the efficacy and safety of HCTZ, chlorthalidone, and indapamide as add-on therapy in patients with hypertension.

Keywords: blood pressure control, hydrochlorothiazide, thiazide-like diuretics, chlorthalidone, indapamide, combined therapy

Importance of blood pressure control

Hypertension is one of the most important risk factors for the development of cardiovascular disease, including stroke, ischemic heart disease, heart failure, and chronic kidney disease. Approximately 54% of stroke, 47% of ischemic heart disease, and 13.5% of total deaths are attributable to hypertension worldwide. This is very relevant, given that more than one third of adults have hypertension. Noteworthy is that although these numbers increase markedly with age, hypertension has become increasingly common in the younger age groups in recent years.

Decreasing blood pressure (BP) levels to recommended targets is essential to improve the cardiovascular prognosis in the hypertensive population. The reduction of coronary heart disease mortality observed in a number of countries has been at least in part associated with improved medical treatment and control of risk factors, particularly with regard to systolic BP and total cholesterol. Data from INVEST...
Importance of combined therapy in the treatment of hypertension

It has been reported that most patients with hypertension need at least two antihypertensive agents to achieve BP goals, particularly patients at higher risk. Combining antihypertensive drugs with different mechanisms of action is a logical approach, because hypertension is caused by multifactorial interacting mechanisms. As a result, the combination of drugs with different mechanisms of action can enhance the antihypertensive efficacy of each agent in monotherapy when combined, and may block counter-regulatory mechanisms, thereby reducing the incidence of side effects. Current guidelines recommend the use of combined therapy when monotherapy fails to attain BP goals, and as a first choice in patients with markedly elevated BP, particularly those at high or very high cardiovascular risk.

Although different antihypertensive drugs can be combined, not all combinations are equally effective and safe. In this context, the combination of a renin angiotensin system inhibitor (either an angiotensin-converting enzyme inhibitor [ACEi] or an angiotensin receptor blocker [ARB]) with a diuretic, usually a thiazide or thiazide-like agent, is specifically recommended. In fact, both types of drugs have synergistic mechanisms of action. The thiazides enhance the activity of the renin angiotensin system, increasing the efficacy of renin angiotensin system inhibitors. Moreover, ACEi and ARB reduce the risk of the side effects associated with diuretics, including hypokalemia and metabolic disturbances (ie, hyperglycemia, insulin resistance, and hyperuricemia). The combination of a renin angiotensin system inhibitor and a diuretic is very common in clinical practice. Thus, in Spain, when combined therapy is required, the combination preferred by general practitioners for most patients is a renin angiotensin system blocker and a diuretic.

Hydrochlorothiazide (HCTZ), chlorthalidone, and indapamide have been diuretics the most frequently used in combination with an ACEi or ARB. However, in clinical practice, the majority of fixed combinations containing a renin angiotensin system inhibitor and a diuretic have included HCTZ. Are there differences between these diuretics? The aim of this review was to analyze the available evidence regarding the efficacy and safety of these drugs alone and as add-on therapy in patients already taking agents that block the renin angiotensin system.

Pharmacokinetics of hydrochlorothiazide, chlorthalidone, and indapamide

HCTZ is a thiazide that is rapidly absorbed after oral intake and reaches peak concentrations in about 2 hours. It has been calculated that the half-life of HCTZ is approximately 8–15 hours with long-term dosing. It is eliminated unchanged in the urine. Different studies have shown that the pharmacodynamic response of HCTZ is much longer than expected from its half-life, supporting once-daily dosing of this drug. On the other hand, it has been reported that doses higher than 25 mg do not markedly increase the antihypertensive efficacy of HCTZ, but are associated with a higher risk of hypokalemia. In contrast, HCTZ doses of 12.5 mg daily, despite being less effective than 25 mg daily, cause less hypokalemia.

Chlorthalidone is a thiazide-like diuretic. After oral intake, peak serum concentrations are achieved in 2–6 hours. The half-life of chlorthalidone is approximately 42 (range 29–55) hours, reaching 45–60 hours after long-term dosing. However, interindividual variability in the half-life of chlorthalidone is wide. Chlorthalidone is excreted unchanged by the kidneys. The natriuretic effect of chlorthalidone is maximal at 18 hours and lasts more than 48 hours. Comparing different doses of chlorthalidone, it has been observed that 25 mg daily is nearly as effective as higher doses, but with less risk of hypokalemia. Other studies have shown that chlorthalidone doses of 12.5 mg and 25 mg daily offer the best efficacy and safety (in terms of hypokalemia) profiles.

Indapamide is a thiazide-like diuretic acting in the proximal segment of the distal tubule, mainly on sodium and chloride excretion and with a lesser effect on potassium or uric acid urine excretion. Indapamide reduces vascular reactivity to pressor amines. It is rapidly absorbed after oral ingestion and is metabolized predominantly in the liver, mainly by cytochrome P450 (CYP)2C9 and CYP3A4 isozymes and by cytosolic hydrolysis enzymes. The plasma elimination half-life is biphasic (14 and 25 hours), and the main route of elimination is via the urine.
Efficacy and safety of HCTZ as add-on therapy

The addition of HCTZ to an ACEi or ARB as a free or fixed combination has been widely investigated and used in clinical practice. In one study, patients with uncontrolled BP despite treatment with HCTZ 25 mg daily were randomized to receive amiloride 2.5–5 mg/day or enalapril 10–20 mg/day. After 12 weeks of treatment, the addition of enalapril was more effective than amiloride for lowering BP, as measured by ambulatory BP monitoring and office systolic BP.33

INCLUSIVE (Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations) was a multicenter, prospective, open-label, single-arm study that aimed to determine the efficacy and safety of a fixed combination of irbesartan and HCTZ in patients with uncontrolled systolic BP after at least 4 weeks of antihypertensive monotherapy. Treatment was sequential, ie, placebo (4–5 weeks), HCTZ 12.5 mg (2 weeks), irbesartan/HCTZ 150/12.5 mg (8 weeks), and irbesartan/HCTZ 300/25 mg (8 weeks). At the end of the study, more than 75% of patients who had been uncontrolled on monotherapy achieved their target systolic BP. All the treatments were well tolerated.34

A number of studies have analyzed the efficacy of combining candesartan with HCTZ.35–38 In a dose-response analysis of a combination of candesartan (2–32 mg) and HCTZ (6.25–25 mg) performed in 4,632 patients with mild to moderate hypertension, the effects of this combination were dose-related over a wide range of doses and additive.35

In the OLMEBEST study, the question of whether dose titration of olmesartan medoxomil (to 40 mg once daily) and olmesartan medoxomil/HCTZ combination therapy (to 20/12.5 mg once daily) was therapeutically equivalent was investigated in 2,306 patients with mild to moderate hypertension that was not controlled on low-dose olmesartan medoxomil monotherapy (20 mg once daily). At the end of the study, both strategies were effective and well tolerated.39

Efficacy and safety of chlorthalidone

Several studies have analyzed the effects of chlorthalidone on reduction of BP levels and on cardiovascular outcomes. Azilsartan medoxomil is the most recent ARB to reach the market. It is currently available as monotherapy or as a fixed-dose combination with chlorthalidone. In a double-blind factorial study, the efficacy and safety of a fixed-dose combination of azilsartan medoxomil and chlorthalidone were compared with those of its individual components in 1,714 patients with a clinic systolic BP of 160–190 mmHg. Patients were randomized to treatment with azilsartan 0 mg, 20 mg, 40 mg, or 80 mg and/or chlorthalidone 0 mg, 12.5 mg, or 25 mg. After 8 weeks of follow-up, combination treatment with azilsartan and chlorthalidone resulted in a substantially greater reduction in systolic BP than that achieved with either drug alone.40 Improvement in BP control using chlorthalidone has been associated with a regression of left ventricular hypertrophy.41

The SHEP (Systolic Hypertension in the Elderly Program) study was performed to assess the ability of antihypertensive drug treatment to reduce the risk of stroke in 4,736 patients ≥60 years with isolated systolic hypertension. The risk of stroke was reduced by 36% using stepped-care antihypertensive treatment, with low-dose chlorthalidone as the step 1 medication (Figure 1).42 Moreover, in the SHEP study, low-dose chlorthalidone effectively reduced the risk of cardiovascular events, including cerebrovascular and cardiac events, regardless of the presence of diabetes.43 Additionally, stepped-care treatment based on low-dose chlorthalidone had a strong protective effect with regard to prevention of heart failure, particularly in patients with a previous history of myocardial infarction.44 The effects of active treatment in the participants randomized to active therapy in SHEP were specifically analyzed after a 22-year follow-up, and it was found that stepped-care chlorthalidone therapy for 4.5 years was associated with a longer life expectancy.45

In a prespecified subgroup analysis of 15,638 women and 17,719 men who participated in ALLHAT (the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), with a total follow-up of 8–13 years (active treatment plus passive surveillance using national administrative databases to ascertain deaths and hospitalizations), the risk of the primary coronary

Figure 1 Effects of chlorthalidone on cardiovascular outcomes.

Note: Data from Roush et al;46 Dorsch et al;49 Dhalla et al. Abbreviations: Chlorthal, chlorthalidone; HCTZ, hydrochlorothiazide; CV, cardiovascular; HF, heart failure; SHEP, Systolic Hypertension in the Elderly Program; vs, versus; NS, not significant.
heart disease outcome and any other cardiovascular disease outcome was similar for amlopidine, lisinopril, and chlorthalidone. However, chlorthalidone-based treatment had the lowest risk of heart failure, irrespective of sex.\textsuperscript{46} Furthermore, in a post hoc analysis of ALLHAT in hypertensive patients with a reduced glomerular filtration rate, the three drugs were similar in terms of reducing the risk of end-stage renal disease or achieving a 50% or greater decrement in glomerular filtration rate.\textsuperscript{47}

Finally, it has been reported that the beneficial effects of chlorthalidone are not limited to its ability to reduce BP, and the pleiotropic effects of chlorthalidone may include improvements in oxidative status, endothelial function, and antiplatelet activity.\textsuperscript{48} Moreover, studies have shown that, compared with placebo, chlorthalidone has minor effects on fasting glucose and total cholesterol,\textsuperscript{49} and compared with HCTZ, significantly reduces total cholesterol and low-density lipoprotein cholesterol levels.\textsuperscript{49}

Hydrochlorothiazide versus chlorthalidone: what is the evidence?

The relative antihypertensive potency and relative cardiovascular risk reduction have been investigated for HCTZ and chlorthalidone.\textsuperscript{50} In a randomized, single-blind, 8-week active treatment crossover study, chlorthalidone 12.5 mg/day (force-titrated to 25 mg/day) and HCTZ 25 mg/day (force-titrated to 50 mg/day) were compared in untreated hypertensive patients. Compared with HCTZ 50 mg/day, chlorthalidone 25 mg/day reduced ambulatory systolic BP more effectively (mean 24-hour reduction $-7.4 \pm 1.7$ mmHg versus $-12.4 \pm 1.8$ mmHg, respectively, $P=0.054$; mean nighttime reduction $-6.4 \pm 1.8$ mmHg versus $-13.5 \pm 1.9$ mmHg, respectively, $P=0.009$). However, these differences were not apparent when office BP measurements were considered (Table 1).\textsuperscript{51}

In a randomized, double-blind, titrate-to-target BP trial, a fixed combination of azilsartan medoxomil and chlorthalidone was compared with a free combination of azilsartan medoxomil and HCTZ in 609 individuals with stage 2 primary hypertension and a mean baseline clinic BP of 164.6/95.4 mmHg. After 2 weeks of treatment with azilsartan medoxomil 40 mg as monotherapy, 12.5 mg of diuretic for 4 weeks (up to week 6) was added to treatment and then titrated to 25 mg for another 4 weeks (up to week 10) if target BP was not achieved. At week 6, the combination containing chlorthalidone achieved a greater reduction in clinic systolic BP ($-35.1$ mmHg versus $-29.5$ mmHg, respectively, mean difference $-5.6$ mmHg; 95% confidence interval [CI] $-8.3$ to $-2.9$; $P<0.001$), as well as a greater reduction in 24-hour ambulatory BP (mean difference $-5.8$ mmHg; 95% CI $-8.4$ to $-3.2$, $P<0.001$). As a result, more patients treated in the chlorthalidone group achieved their target BP at week 6 (64.1% versus 45.9%, $P<0.001$), without a significant increase in drug discontinuations due to adverse events (Table 1).\textsuperscript{52}

In a meta-analysis analyzing the dose-response relationship between HCTZ, chlorthalidone, and bendroflumethiazide with regard to BP and serum potassium and urate levels, 26 studies of HCTZ, three of chlorthalidone, and one of bendroflumethiazide were included, providing a total of 4,683 subjects in more than 53 comparison arms. Meta-regression of the effect of thiazides on systolic BP showed different antihypertensive effects, ie, bendroflumethiazide lowered BP more than chlorthalidone, and chlorthalidone lowered BP more than HCTZ. Similar findings were reported for diastolic BP (Table 1).\textsuperscript{53} The results of this study strongly suggest that 25 mg of HCTZ should not be regarded as equivalent to 25 mg of chlorthalidone.\textsuperscript{53}

Another meta-analysis studying the effects of HCTZ and chlorthalidone on systolic BP and potassium levels included 108 clinical trials with HCTZ and 29 with chlorthalidone. Equivalence analysis suggested that the systolic BP reductions achieved with HCTZ and chlorthalidone were not equivalent within the low-dose range currently recommended. In fact, when evaluated on a milligram-per-milligram basis, chlorthalidone generally produced slightly greater reductions in systolic BP. In contrast, within the same dosing range, the mean changes in potassium were similar (Table 1).\textsuperscript{54}

In a retrospective study comparing the effects of switching from HCTZ to chlorthalidone in a population from the Veterans Affairs Ann Arbor Healthcare System, in which nearly three quarters of patients were taking three or more antihypertensive agents at the time of the medication change, there was a significant reduction in both systolic BP ($-15.8$ mmHg; 95% CI $-8.9$ to $-22.6$ mmHg, $P<0.0001$) and diastolic BP ($-4.2$ mmHg; 95% CI $-1.5$ to $-6.9$ mmHg, $P=0.0035$, Table 1).\textsuperscript{55} A more recent study showed that, when combined with candesartan 8 mg, chlorthalidone 12.5 mg was as effective as HCTZ 25 mg in reducing central aortic pressure. However, whereas chlorthalidone significantly reduced pulse wave velocity, HCTZ only marginally reduced the augmentation index (Table 1).\textsuperscript{56}

These beneficial effects of chlorthalidone over HCTZ with regard to BP levels translate into an improvement in
Table 1 Summary of the most relevant studies comparing the efficacy of hydrochlorothiazide with chlorthalidone in patients with hypertension

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ernst et al[1]</td>
<td>Randomized, single-blind, 8-week, active treatment, crossover study in which chlorthalidone 12.5 mg/day (force-titrated to 25 mg/day) and HCTZ 25 mg/day (force-titrated to 50 mg/day) were compared in patients with untreated hypertension. Thirty patients completed the first active treatment period, whereas 24 patients completed both.</td>
<td>Compared with HCTZ 50 mg/day, chlorthalidone 25 mg/day reduced ambulatory systolic BP more effectively (24-hour mean −7.4±1.7 mmHg versus −12.4±1.8 mmHg, respectively; P=0.054; nighttime mean −6.4±1.8 mmHg versus −13.5±1.9 mmHg, respectively; P=0.009). However, these differences were not apparent when office BP measurements were considered (at study end, −10.8±3.5 versus −17.1±3.7, respectively; P=0.84). At week 6, the combination containing chlorthalidone achieved greater clinic systolic BP reductions (−35.1 mmHg versus −29.5 mmHg, mean difference −5.6 mmHg; P&lt;0.001), as well as greater 24-hour ambulatory BP reduction (mean difference −5.8 mmHg; P&lt;0.001). More patients in the chlorthalidone group achieved target BP at week 6 (64.1% versus 45.9%, P&lt;0.001). Discontinuation due to adverse events was similar between treated and control groups. (9.3% versus 7.3%, P=0.38).</td>
</tr>
<tr>
<td>Bakris et al[2]</td>
<td>Randomized, double-blind, titrate-to-target BP trial. A fixed combination of azilsartan medoxomil and chlorthalidone was compared with coadministration of azilsartan medoxomil and HCTZ in 609 individuals with stage 2 primary hypertension (mean baseline clinic BP 164.6/95.4 mmHg). After 2 weeks of treatment with azilsartan medoxomil 40 mg as monotherapy, 12.5 mg of diuretic for 4 weeks (up to week 6) was added to treatment and then titrated to 25 mg for another 4 weeks (up to week 10) if BP targets were not achieved.</td>
<td>Metaregression of the effect of thiazides on systolic BP showed various antihypertensive effects, as follows: bendroflumethiazide &gt; chlorthalidone &gt; HCTZ (the dose of each agent estimated to reduce systolic BP by 10 mmHg was 1.4, 8.6, and 26.4 mg, respectively). Similar findings were found regarding diastolic BP.</td>
</tr>
<tr>
<td>Peterzan et al[3]</td>
<td>Meta-analysis aiming to analyze the dose-response relationships between HCTZ, chlorthalidone, and bendroflumethiazide on BP, serum potassium, and urate. A total of 26 trials examining HCTZ, three investigating chlorthalidone, and one investigating bendroflumethiazide were included, with a total of 4,683 subjects in more than 53 comparison arms.</td>
<td>Equivalence analysis suggested that the systolic BP reductions achieved with HCTZ and chlorthalidone were not equivalent within the low-dose range currently recommended. When evaluated on a milligram-per-milligram basis, chlorthalidone generally produced slightly greater reductions in systolic BP. By contrast, within the same dosing range, the mean changes in potassium were similar. There was a significant reduction in both systolic BP (−15.8 mmHg; P&lt;0.0001) and diastolic BP (−4.2 mmHg; P=0.0035).</td>
</tr>
<tr>
<td>Ernst et al[4]</td>
<td>Meta-analysis that studied the effects of HCTZ and chlorthalidone on systolic BP and potassium. A total of 108 clinical trials with HCTZ and 29 with chlorthalidone were included from 1948 to July 2008.</td>
<td></td>
</tr>
<tr>
<td>Matthews et al[5]</td>
<td>Retrospective study comparing the effects of changing from HCTZ to chlorthalidone in a veteran population (n=40) from Veterans Affairs Ann Arbor Healthcare System, in which nearly three quarters of patients were taking three or more antihypertensive agents at the time of the medication change.</td>
<td></td>
</tr>
<tr>
<td>Kwon et al[6]</td>
<td>Open-label, randomized, prospective crossover study with an 8-week active treatment (candesartan 8 mg with HCTZ 25 mg or chlorthalidone 12.5 mg) and a 4-week washout period (only candesartan during this period). Twenty-eight treatment-naïve hypertensive patients were included.</td>
<td>Combined with candesartan 8mg, chlorthalidone 12.5mg was as effective as HCTZ 25mg in reducing central aortic pressure. However, whereas chlorthalidone significantly reduced pulse wave velocity, HCTZ only marginally reduced the augmentation index.</td>
</tr>
<tr>
<td>Dorsch et al[7]</td>
<td>Retrospective cohort analysis from the Multiple Risk Factor Intervention Trial (this trial was a primary prevention cardiovascular trial in which participants were men aged 35–57 years and enrolled in 1973).</td>
<td>Although both drugs reduced cardiovascular events compared to those who took neither drug, chlorthalidone reduced cardiovascular events more effectively than HCTZ (by 49% and 35%, respectively; P&lt;0.0001 in both cases versus neither drug; P=0.0016 between both drugs).</td>
</tr>
</tbody>
</table>

(Continued)
Table I (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roush et al59</td>
<td>Systematic review of randomized trials in which one arm was based on either HCTZ or chlorthalidone, followed by two types of network meta-analyses, ie, a drug-adjusted analysis and an office systolic BP-adjusted analysis. A total of three trials based on HCTZ and six based on chlorthalidone were included.</td>
<td>In the drug-adjusted analysis (n=50,946), compared with HCTZ, chlorthalidone reduced the risk of congestive heart failure by 23% (P=0.032); the risk for all cardiovascular events was 21% (P&lt;0.0001). In the office systolic BP-adjusted analysis (n=78,350), compared with HCTZ, chlorthalidone reduced the risk of cardiovascular events by 18% (P=0.024). Chlorthalidone was not associated with fewer adverse cardiovascular events or deaths compared with HCTZ (adjusted HR 0.93; 95% CI 0.81–1.06).</td>
</tr>
<tr>
<td>Dhalla et al60</td>
<td>Propensity score-matched observational cohort study with up to 5 years of follow-up performed in patients ≥66 years who were newly treated with chlorthalidone or HCTZ and had not been hospitalized for heart failure, stroke, or myocardial infarction in the previous year (n=29,873).</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: HCTZ, hydrochlorothiazide; BP, blood pressure; CI, confidence interval; HR, hazards ratio.

terms of subclinical organ damage. Data from the Multiple Risk Factor Intervention Trial showed that, at the individual level, the Sokolow-Lyon index and left ventricular mass were significantly lower in men receiving chlorthalidone than in those receiving HCTZ at 48 months and 84 months of follow-up.57 It has also been observed that chlorthalidone is significantly more effective than bendroflumethiazide (a thiazide diuretic) in reducing epinephrine-mediated platelet aggregation. Moreover, although both diuretics reduced vascular permeability to albumin, only chlorthalidone increased angiogenesis.58

More importantly, other studies have investigated whether these beneficial properties of chlorthalidone when compared with HCTZ result in better cardiovascular outcomes. A retrospective cohort analysis from the Multiple Risk Factor Intervention Trial showed that, in hypertensive patients at high risk of cardiovascular events, although both drugs reduced cardiovascular events compared with those who took neither drug, chlorthalidone reduced cardiovascular events more effectively than HCTZ (Table 1 and Figure 1).59

A systematic review of randomized trials in which one arm was based on either HCTZ or chlorthalidone, followed by two types of network meta-analyses, ie, a drug-adjusted analysis and an office systolic BP-adjusted analysis, included three trials based on HCTZ and six based on chlorthalidone. In the drug-adjusted analysis (n=50,946), compared with HCTZ, chlorthalidone reduced the risk of congestive heart failure by 23% (95% CI 2–39, P=0.032), and the risk for all cardiovascular events was 21% (95% CI 12–28, P<0.0001). In the office systolic BP-adjusted analysis (n=78,350), compared with HCTZ, chlorthalidone reduced the risk of cardiovascular events by 18% (95% CI 3–30, P=0.024, Table 1 and Figure 1).59 However, other studies showed that, in older adults, chlorthalidone as typically prescribed was not associated with fewer adverse cardiovascular events or deaths compared with HCTZ (Table 1 and Figure 1).60

As a result, the question concerning whether chlorthalidone is better than HCTZ at reducing cardiovascular events in hypertensive patients remains unresolved. Head-to-head trials have shown that chlorthalidone is more effective than HCTZ in reducing BP levels, particularly during the nighttime due to the longer duration of action of chlorthalidone, and in decreasing left ventricular hypertrophy. Moreover, although no head-to-head outcomes trials comparing the efficacy of chlorthalidone and HCTZ are available, and data regarding this issue is provided from post hoc analyses, the majority of the studies have shown superiority for chlorthalidone in reducing cardiovascular events, probably not only due to the higher antihypertensive efficacy of chlorthalidone but also as a result of its pleiotropic effects.61

Despite the guidelines, such as those of the National Institute for Health and Clinical Excellence, recommending that when a diuretic is prescribed, a thiazide-like diuretic, such as chlorthalidone or indapamide, should be preferred over bendroflumethiazide or HCTZ,62 the fact is that prescriptions for HCTZ outnumber those for chlorthalidone by more than 20-fold.69

**Efficacy and safety of indapamide**

Several studies have analyzed the efficacy and safety of indapamide as add-on therapy, particularly with perindopril and delapril. A 9-month study comparing the efficacy and tolerability of three different strategies for the treatment of hypertension, ie, a low-dose combination (perindopril 2 mg and indapamide 0.625 mg with the possibility to increase to 4 and 1.25 mg, respectively), sequential mono-therapy (treatment initiated with atenolol 50 mg, replaced if necessary by losartan 50 mg, and then by amlodipine 5 mg),
and stepped-care (valsartan 40 mg, then 80 mg, and finally if required the addition of HCTZ 12.5 mg), included 533 patients with uncomplicated essential hypertension. At the end of the study, 62% of patients in the low-dose combination group achieved their target BP, compared with 49% in the sequential monotherapy group (P=0.02) and 47% in the stepped-care group (P=0.005). This better BP control was not associated with an increase in side effects.63

In a 3-month, open-label, observational study, outpatients with hypertension who did not attain their target BP with antihypertensive treatment were included if their treating physician switched them to fixed-dose perindopril 10 mg/indapamide 2.5 mg according to the clinical criteria of the physicians. Nearly 9,300 patients were enrolled. At the end of the study, 72.7% of patients had achieved their BP goal. Reductions in total cholesterol, low-density lipoprotein cholesterol, triglycerides, fasting glucose, and uric acid levels were clinically significant, without changes in sodium or potassium levels. These changes in the metabolic profile were likely due to withdrawal of previous treatment with thiazides and beta-blockers.64

In a 6-month, prospective, open-label clinical study performed in 397 patients with hypertension and type 2 diabetes, a fixed-dose combination of perindopril/indapamide (from 5/1.25 mg to 10/2.5 mg if BP targets were not attained) was prescribed (started, switched, or added to previous therapy). At the end of the study, 84% of patients taking perindopril/indapamide 5/1.25 mg alone and 90% of patients taking perindopril/indapamide 10/2.5 mg alone showed normalization of their BP levels, with good tolerability. Microalbuminuria decreased in 75% of patients with microalbuminuria.65

In another study performed in more than 2,300 hypertensive patients being seen in daily clinical practice, 69% of whom had been unsuccessfully treated with other antihypertensive agents, 4.6% of whom had not tolerated previous treatments, and 26.8% of whom were newly diagnosed with hypertension, 87.1% achieved their target BP after 3 months of treatment with perindopril/indapamide (2.5/0.625 mg or 5/1.25 mg uptitrated to 10/2.5 mg at any time during the study if required). BP reductions were similar, irrespective of the presence of diabetes mellitus, metabolic syndrome, or left ventricular hypertrophy. Moreover, no significant changes in laboratory parameters were observed and patient quality of life was improved.66

In a systematic review of the efficacy and safety of a perindopril/indapamide 2 mg/0.625 mg combination as first-line treatment for hypertension, a total of 11 trials with 5,936 individuals (five studies versus placebo and six studies versus routine antihypertensive agents) were included. Compared with placebo, the combination of perindopril/indapamide effectively reduced BP levels (systolic BP −9.03 mmHg, P<0.01; diastolic BP −5.09 mmHg, P<0.01). Similarly, compared with routine antihypertensive agents, the combination of perindopril/indapamide was more effective in reducing BP (systolic BP −3.72 mmHg, P=0.03; diastolic BP −1.71 mmHg, P<0.01). Adverse events and withdrawal rates were similar between the perindopril-indapamide group and the placebo or routine antihypertensive drug groups.67

Regarding organ damage, the ADVANCE (Action in Diabetes and Vascular Disease) Echocardiography Substudy showed that although the perindopril-indapamide combination did not improve left ventricular diastolic function in patients with diabetes to a greater extent than placebo, this combination significantly reduced BP and left ventricular mass.68

Moreover, it was reported that approximately 85% of physicians considered the efficacy and tolerability of perindopril/indapamide 2/0.625 mg in hypertensive patients with diabetes seen in daily clinical practice to be “good” or “very good” and that 93% of patients were “satisfied” or “very satisfied” with this therapy.69

On the other hand, it has been shown that the combination of perindopril and indapamide has additional beneficial effects. Improvements in vascular function have been demonstrated in hypertensive patients by a reduction in wave reflection, lowering of peripheral arterial stiffness, and improvement in endothelial function,70 and reductions in BP and left ventricular mass index in hypertensive patients with left ventricular hypertrophy, along with improvements in resting and hyperemic myocardial blood flow.71 Experimental data in rats have shown that the improvements in coronary flow observed with this combination are due to reverse remodeling of intramural coronary arterioles and improved microvascular function.71 Moreover, it has been reported that indapamide decreases BP, left ventricular hypertrophy, and the collagen ratio.72

Perhaps more importantly, clinical trials have investigated the benefits of the combination of perindopril and indapamide with regard to cardiovascular outcomes. PROGRESS (Perindopril PROtection aGainst REcurrent Stroke Study) was performed to assess the effects of perindopril (4 mg daily), with the addition of indapamide at the discretion of treating physicians, in patients with a history of stroke or transient ischemic attack, irrespective of the presence of
Hypertension. A total of 6,105 individuals were randomized to active treatment or placebo. After 4 years of follow-up, active treatment was associated with a 28% reduction in the risk of stroke (43% in those treated with the combined therapy), and a 26% reduction in the risk of total major vascular events (Figure 2).73

In ADVANCE, the effects of a combination of perindopril and indapamide on serious vascular events were investigated in 11,140 patients with type 2 diabetes, irrespective of their initial BP levels or use of antihypertensive drugs. Patients were randomized to active treatment or placebo in addition to current therapy. After a mean follow-up of 4.3 years, the perindopril/indapamide combination was associated with a 9% reduction in the risk of major macrovascular or microvascular events (hazards ratio [HR] 0.91; 95% CI 0.83–1.00, P=0.04), an 18% reduction in the risk of death from cardiovascular disease (HR 0.82; 95% CI 0.68–0.98, P=0.03), and a 14% reduction in risk of death from any cause (HR 0.86; 95% CI 0.75–0.98, P=0.03, Figure 2).74 A sub-study of ADVANCE showed that active treatment with a combination of perindopril and indapamide reduced BP levels safely and reduced the risk of major clinical outcomes in patients with type 2 diabetes and aged over 75 years.75 Similarly, the beneficial effects of the perindopril/indapamide combination on cardiovascular and renal outcomes and death were consistent across all stages of chronic kidney disease at baseline.76

In HYVET (the Hypertension in the Very Elderly Trial), 3,845 patients (aged ≥80 years) with hypertension and a sustained systolic BP ≥160 mmHg were randomized to indapamide (sustained-release, 1.5 mg) or placebo. Perindopril (2 or 4 mg) or placebo was added when required to achieve a BP goal <150/80 mmHg. After a mean follow-up of 1.8 years, active treatment was associated with a 30% reduction in the risk of fatal or nonfatal stroke (P=0.06), a 39% reduction in the risk of death from stroke (P=0.05), a 21% reduction in the risk of death from any cause (P=0.02), a 23% reduction in the risk of death from cardiovascular causes (P=0.06), and a 64% reduction in the risk of heart failure (P<0.001, Figure 2).77

In the 1-year, open-label active treatment extension of HYVET, patients on active treatment continued taking the active drug, and those initially assigned to placebo received active BP-lowering treatment. Those patients initially assigned to active treatment had less total mortality (HR 0.48; 95% CI 0.26–0.87, P=0.02) and cardiovascular mortality (HR 0.19; 95% CI 0.04–0.87, P=0.03).78

On the other hand, other studies have analyzed the antihypertensive efficacy of a combination of indapamide and delapril in hypertensive patients.79–82 In DIMS II (Delapril-Indapamide Multicenter Study II), approximately 800 patients with uncomplicated mild to moderate hypertension were randomized to receive delapril/indapamide or captopril/HCTZ for 6 months. At the end of the study, more patients treated with delapril/indapamide responded to treatment (92.6% versus 85.2%, P<0.001). Side effects occurred in 7.6% and 8.1% of patients, respectively.80 Moreover, in elderly patients aged 65–85 years with a sitting BP of 160–200/95–115 mmHg, the combination of delapril 30 mg plus indapamide 1.25 mg once daily effectively reduced BP levels as well as left ventricular mass index.81 Similarly, treatment with this combination was associated with a significant increase in glomerular filtration rate.82

**Hydrochlorothiazide versus indapamide: what is the evidence?**

As with chlorothalidone, several studies have determined the relative antihypertensive efficacy and relative cardiovascular risk reduction for HCTZ and indapamide. It has been observed in hypertensive patients aged 65–80 years that, indapamide sustained-release was an effective and well tolerated antihypertensive therapy over a 12-month period, even after a switch from amlodipine or HCTZ (Table 2).83 In a small randomized clinical trial of patients with I–II degree high and very high risk hypertension, after 6 months of treatment, the fixed combination of perindopril-induced (indapamide 4/1.25 mg was superior to a combination of captopril/HCTZ 50/25 mg (Table 2).84

In a Russian study, administration of perindopril arginine/indapamide (10 mg/2.5 mg) instead of ACEi or ARB plus
HCTZ in more than 2,100 patients with inadequately controlled hypertension significantly reduced BP levels from 177/99 mmHg to 149/89 mmHg after 2 weeks of treatment, and to 130/80 mmHg after 3 months of treatment, with good tolerance of medication (Table 2).  

In a randomized 12-week study, fixed combinations of delapril (30 mg) plus indapamide (2.5 mg) and fosinopril (20 mg) plus HCTZ (12.5 mg) were compared in 171 patients with mild to moderate hypertension; the proportion of patients who achieved normal BP, defined as a sitting diastolic BP ≤90 mmHg, was similar between the groups (87.4% versus 81%, respectively) and also with regard to those who responded to therapy, defined as a sitting diastolic BP reduction of 10 mmHg or diastolic BP ≤90 mmHg (92% versus 86.9%, respectively). Both combinations were well tolerated (Table 2).

A meta-analysis comparing the efficacy and safety of a combination of delapril and indapamide with different ACEI/HCTZ combinations in patients with mild to moderate hypertension included four head-to-head randomized controlled trials (n=643 and 629, respectively). The proportion of patients who achieved normal BP values or were responders was higher with the delapril/indapamide combination (P=0.024 and P=0.002, respectively). Moreover, the number of withdrawals due to drug-related side effects was lower with the delapril/indapamide combination (2.3% versus 4.8%, respectively, P=0.018).

Table 2 Summary of most relevant studies comparing the efficacy of hydrochlorothiazide with indapamide in patients with hypertension

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonetti et al</td>
<td>Open, 12-month, follow-up study of 444 patients treated with indapamide SR, who were responders and/or achieved target BP levels following a 3-month, randomized, controlled, double-blind, short-term comparison of indapamide SR versus HCTZ 25 mg and amloidpine 5 mg. After 12 months of follow-up, treatment with indapamide SR was associated with a reduction of BP (−24.0−13.1 mmHg); 80.1% of patients achieved their BP goals.</td>
<td></td>
</tr>
<tr>
<td>Nedogoda et al</td>
<td>Clinical trial in which 40 patients with I–II degree high and very high risk hypertension were randomized to receive fixed-dose combinations of perindopril/indapamide 4/1.25 mg or captopril/HCTZ 50/25 mg. After 6 months of treatment, the fixed combination of perindopril/indapamide 4/1.25 mg was superior to the combination of captopril/HCTZ 50/25 mg. Treatment with the perindopril arginine/indapamide combination significantly reduced BP levels from 177/99 mmHg to 149/89 mmHg after 2 weeks of treatment and to 130/80 mmHg after 3 months of treatment, with good tolerance of medication.</td>
<td></td>
</tr>
<tr>
<td>Karpov et al</td>
<td>In this study, perindopril arginine/indapamide (10 mg/2.5 mg) was administered instead of an ACEi or ARB plus HCTZ in more than 2,100 patients with inadequately controlled hypertension. The proportion of patients with normalized BP was similar between the two groups (87.4% versus 81%) and for those who responded to therapy (92% versus 86.9%, respectively). Both combinations were well tolerated.</td>
<td></td>
</tr>
<tr>
<td>Cremonesi et al</td>
<td>In this 12-week randomized study, fixed combinations of delapril/indapamide 30/2.5 mg and fosinopril/HCTZ 20/12.5 mg were compared in 171 patients with mild to moderate hypertension. Normalization of BP was defined as sitting diastolic BP ≤90 mmHg and responders as those having a sitting diastolic BP reduction of 10 mmHg or diastolic BP ≤90 mmHg. The proportion of patients with normalized BP values (OR 1.32; 95% CI 1.04–1.68; P=0.024) and who were responders (OR 1.58; 95% CI 1.22–2.04; P=0.002) were higher with the delapril/indapamide combination. The proportion of patients who withdrew from treatment due to side effects was lower with the delapril/indapamide combination (2.3% versus 4.8%; P=0.018).</td>
<td></td>
</tr>
<tr>
<td>Circelli et al</td>
<td>Meta-analysis comparing the efficacy and safety of a combination of delapril and indapamide with that of different ACEi plus HCTZ combinations in patients with mild to moderate hypertension. Four head-to-head randomized controlled trials (n=643 and n=629, respectively) were included. The proportions of patients with normalized BP values (OR 1.32; 95% CI 1.04–1.68; P=0.024) and who were responders (OR 1.58; 95% CI 1.22–2.04; P=0.002) were higher with the delapril/indapamide combination. The proportion of patients who withdrew from treatment due to side effects was lower with the delapril/indapamide combination (2.3% versus 4.8%; P=0.018).</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: HCTZ, hydrochlorothiazide; BP, blood pressure; CI, confidence interval; OR, odds ratio; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SR, sustained release.
triglycerides (+15.3%, P<0.05) and glucose levels (+12.2%, P<0.05). Moreover, there was a tendency for endothelium-dependent vasodilation to improve with indapamide and become worse with HCTZ. Finally, in an experimental study performed in rats, treatment with losartan was associated with antiatherogenic activity, reflected by lipid-lowering and an antioxidant effect in erythrocytes. However, whereas this activity was abolished by addition of HCTZ to losartan, it remained unchanged when indapamide was added. Moreover, in contrast with indapamide, treatment with HCTZ was associated with hypokalemia.

**Conclusion and place in therapy**

When considering antihypertensive drugs as monotherapy, although the JNC 7 (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) indicated that five classes should be considered as initial therapy and recommended thiazide-type diuretics as initial therapy for most patients, the JNC 8 recommends selection between four specific medication classes (ACEi, ARB, calcium channel blockers, and diuretics). Moreover, the 2013 European guidelines reconfirm that all major classes of antihypertensive agents (diuretics, beta-blockers, calcium channel blockers, ACEi, and ARB) are suitable for the initiation and maintenance of antihypertensive therapy. As a result, it is very likely that diuretics will no longer be recommended as the only first option in monotherapy. Of note, when a diuretic is used for the treatment of hypertension, thiazide and thiazide-like diuretics are mainly prescribed. Loop diuretics are not recommended for the treatment of hypertension, except in the event of advanced renal impairment, and are commonly prescribed when heart failure is also present.

The addition of diuretics to an ACEi or ARB for reducing BP to recommended targets is an adequate choice in patients with hypertension. Thiazides, mainly HCTZ and thiazide-type diuretics, such as chlorthalidone and indapamide, have been widely used for this purpose. However, not all diuretics seem to be equal, as evident in this review. Thus, given that the plasma elimination half-lives of chlorthalidone and indapamide are longer than that of HCTZ, better antihypertensive efficacy over 24 hours may be assured using these agents. In fact, the majority of studies have shown greater BP reductions with chlorthalidone or indapamide than with HCTZ.

Moreover, chlorthalidone and indapamide have shown some clinically relevant additional benefits. Chlorthalidone can reduce platelet aggregation and vascular permeability, stimulate angiogenesis, and improve oxidative status, endothelial function, and antiplatelet activity. Moreover, compared with placebo, chlorthalidone has only small effects on fasting glucose and total cholesterol, and compared with HCTZ, chlorthalidone is associated with significantly lower total cholesterol and low-density lipoprotein cholesterol levels. Similarly, indapamide has demonstrated no negative impact on glucose or lipid metabolism.

However, more importantly, although addition of HCTZ to renin angiotensin system inhibitors has been shown to effectively reduce BP levels, and decreasing BP to recommended targets improves the cardiovascular prognosis, a reduction in outcomes using low doses of HCTZ as add-on therapy has not yet been demonstrated. In contrast, although head-to-head clinical outcomes trials comparing the effects of indapamide or chlorthalidone with HCTZ are not available, indirect comparisons and post hoc analyses suggest that the use of chlorthalidone or indapamide is associated with a reduction in cardiovascular events. On the other hand, the benefits of indapamide with regard to cardiovascular outcomes have been shown only when indapamide is combined with perindopril, but not with other antihypertensive drugs.

Finally, hypokalemia is a potential side effect of thiazide and thiazide-like diuretics that may decrease the beneficial effects of these drugs in patients with hypertension. However, the risk of hypokalemia at the doses usually prescribed for this purpose is low. Moreover, combination with renin angiotensin system inhibitors may reduce this potential limitation. Despite that, addition of potassium supplements or potassium-sparing diuretics, including aldosterone receptor blockers (such as spironolactone and eplerenone) or epithelial sodium channel blockers (such as amiloride and triamterene) can sometimes be necessary, depending on the clinical characteristics of the patient. Combination with an aldosterone receptor blocker may be particularly beneficial in hypertensive patients with heart failure.

Despite these limitations, the evidence suggests that the use of a thiazide-like diuretic, such as chlorthalidone or indapamide, appears to be a preferable option over HCTZ when combined therapy with a renin angiotensin system inhibitor is required. However, the diuretic used most often as add-on therapy in clinical practice is HCTZ.

**Disclosure**

The authors have no conflicts of interests directly related to this work.
References


